- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05452616
Same-day Versus Rapid ART Initiation in HIV-positive Individuals Presenting With Symptoms of Tuberculosis (SaDAPT)
Same-day Versus Rapid ART Initiation in HIV-positive Individuals Presenting With Symptoms of Tuberculosis: an Open-label Randomized Non-inferiority Trial in Lesotho and Blantyre District, Malawi
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
In this randomized controlled trial (RCT) two different, guideline-approved algorithms for antiretroviral therapy (ART) initiation in people living with HIV (PLHIV) with presumptive Tuberculosis (TB), but no signs of central nervous system (CNS) disease will be compared. In one arm, same-day initiation (SDI) of ART will be applied ("ART first") for all participants independent of the status or results of initial TB investigations. In the other arm, an approach with deferral of ART initiation until TB is excluded or confirmed and TB treatment initiated will be applied ("TB results first"). The direct comparison of the two approaches in a pragmatic, two-country RCT conducted in a representative high-prevalence setting will provide evidence on the open question of optimal timing of ART initiation in the large subgroup of PLHIV with presumptive TB outside the CNS.
Serum proteome sub- study: Prediction of clinical phenotypes in people living with HIV using the serum proteome. In a laboratory-based sub-study the plasma samples and clinical data collected as part of SaDAPT trial and ART initiation cohort at the study sites in Lesotho are used. The samples are screened for circulating inflammatory markers using proteomics in PLHIV with high risk of active TB and Immune reconstitution inflammatory syndrome (IRIS). The proteome will be deconvoluted using computational biology with the aim to develop diagnostics for active TB disease and predictors for IRIS.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Niklaus Labhardt, Prof. Dr. DTM&H, MIH
- Phone Number: +41 79 870 18 59
- Email: Niklaus.Labhardt@usb.ch
Study Contact Backup
- Name: Felix Gerber, M Med
- Email: felix.gerber@swisstph.ch
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- 12 years or older
- HIV-positive
- Not taking ART (naïve or reported no ART intake since 90 days or more)
- Presenting with one or more TB symptoms according to W4SS
- Unknown TB status
- Planning to continue care at the study facility for at least 30 weeks
- Willing and able to consent (age 18 years or older) or assent with guardian consent (age 12 to 17 years)
Exclusion Criteria:
- Medical condition requiring admission or referral to a higher level health facility at enrolment
- Symptoms or clinical signs suggestive for diseases of the CNS
- Positive cryptococcal antigen test (CrAg)
- Reporting to be pregnant
- Taking TB treatment, TB preventive therapy (TPT) or treatment against cryptococcal meningitis
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: "ART first" arm
ART initiation on the day of enrolment independent of TB investigations
|
ART initiation on the day of enrolment independent of TB investigations in PLHIV with presumptive TB but no signs of CNS disease.
The trial uses treatments and drug-doses as per international and national guidelines.
All treatment components will be applied at standard dosage and no new substances or alternative indications will be tested.
|
Active Comparator: "TB results first" arm
ART initiation only after active TB has been refuted or confirmed
|
Deferral of ART initiation until active TB has been refuted or confirmed.
PLHIV presenting with symptoms (cough, fever, night sweat, weight loss) are defined as presumptive TB, and should have microbiological TB investigations.
Routine TB investigations in Malawi and Lesotho usually consist of two sputum bottles for analysis using nucleic acid amplification tests (Xpert MTB/RIF (Ultra)).The trial uses treatments and drug-doses as per international and national guidelines.
All treatment components will be applied at standard dosage and no new substances or alternative indications will be tested.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
HIV viral suppression <400 copies/mL
Time Frame: 26 (22 - 40) weeks after enrolment
|
HIV viral suppression <400 copies/mL (obtained from routine laboratory reports at study facility, from laboratory reports of referral facility in case of transfer out, or from dried blood spot (DBS) sample for participants without documented clinic visit but found during home visit tracing)
|
26 (22 - 40) weeks after enrolment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Retention in care
Time Frame: 26 (22 - 30) weeks after enrolment
|
Retention in care, defined as a documented ART clinic visit between 22 and 30 weeks after enrolment
|
26 (22 - 30) weeks after enrolment
|
Engagement in care
Time Frame: 26 (22 - 30) weeks after enrolment
|
Engagement in care, defined as reporting regular ART intake, irrespective if a documented visit took place between 22 and 30 weeks after enrolment
|
26 (22 - 30) weeks after enrolment
|
Disengagement from care
Time Frame: 26 (22 - 30) weeks after enrolment
|
Disengagement from care, defined as non-engaged in care but reached through patient tracing
|
26 (22 - 30) weeks after enrolment
|
Lost to follow-up
Time Frame: 26 (22 - 30) weeks after enrolment
|
Lost to follow-up, defined as non-retained in care and not reached through tracing
|
26 (22 - 30) weeks after enrolment
|
Non-traumatic mortality
Time Frame: during the first 30 weeks after enrolment
|
Non-traumatic mortality
|
during the first 30 weeks after enrolment
|
Serious adverse events (SAEs)
Time Frame: during the first 30 weeks after enrolment
|
SAEs
|
during the first 30 weeks after enrolment
|
TB-Immune reconstitution inflammatory syndrome (IRIS)
Time Frame: during the first 30 weeks after enrolment
|
TB-Immune reconstitution inflammatory syndrome (IRIS) is defined as Adverse event of special interest (AESIs): AESIs
|
during the first 30 weeks after enrolment
|
Incidence of TB disease (microbiologically confirmed and/or clinical diagnosis)
Time Frame: during the first 30 weeks after enrolment
|
Incidence of TB disease (microbiologically confirmed and/or clinical diagnosis), defined as any TB diagnosis after enrolment not classified as prevalent TB at enrolment
|
during the first 30 weeks after enrolment
|
HIV viral suppression
Time Frame: at 26 (22 - 40) weeks
|
HIV viral suppression using different thresholds (<20 copies/mL; <100 copies/mL; <1000 copies/mL)
|
at 26 (22 - 40) weeks
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Prevalence of active TB diagnosed at enrolment (exploratory endpoint)
Time Frame: up to a maximum of 28 days after enrolment
|
Prevalence of active TB, defined as TB diagnosed clinically or microbiologically through the TB investigations at enrolment
|
up to a maximum of 28 days after enrolment
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Rachael Mary Burke, BMBCh, MSc, DTM&H, London School of Hygiene and Tropical Medicine
- Principal Investigator: Niklaus Labhardt, Prof. Dr. DTM&H, MIH, Division of Clinical Epidemiology, University Hospital Basel
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
- TB preventive treatment
- Antiretroviral therapy (ART)
- Tuberculosis (TB) infection
- Acquired immunodeficiency syndrome
- Immune reconstitution inflammatory syndrome
- People living with HIV (PLHIV)
- Same-day initiation (SDI) of ART
- Sub-Saharan African countries
- HIV/TB-coinfection
- immune reconstitution inflammatory syndrome (IRIS)
Additional Relevant MeSH Terms
- RNA Virus Infections
- Virus Diseases
- Infections
- Blood-Borne Infections
- Communicable Diseases
- Sexually Transmitted Diseases, Viral
- Sexually Transmitted Diseases
- Lentivirus Infections
- Retroviridae Infections
- Immune System Diseases
- Bacterial Infections
- Bacterial Infections and Mycoses
- Gram-Positive Bacterial Infections
- Actinomycetales Infections
- Mycobacterium Infections
- Slow Virus Diseases
- Urogenital Diseases
- Genital Diseases
- HIV Infections
- Tuberculosis
- Acquired Immunodeficiency Syndrome
- Immunologic Deficiency Syndromes
Other Study ID Numbers
- AO_2022-00031; am22Labhardt
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Human Immunodeficiency Virus (HIV) Infection
-
GlaxoSmithKlineCompletedHIV Infection | HIV-1 Infection | Infection, Human Immunodeficiency Virus INetherlands, Finland, Ireland, Portugal, Switzerland
-
University College, LondonLondon School of Hygiene and Tropical Medicine; MRC/UVRI and LSHTM Uganda Research... and other collaboratorsRecruitingHIV Infections | Hiv | HIV-1-infection | Paediatric Human Immunodeficiency Virus InfectionUganda, Zimbabwe, South Africa, Kenya
-
GlaxoSmithKlineCompletedHIV Infection | Infection, Human Immunodeficiency VirusUnited States, Puerto Rico
-
Merck Sharp & Dohme LLCWithdrawnHuman Immunodeficiency Virus (HIV) Infections
-
GlaxoSmithKlineCompletedHIV Infection | Infection, Human Immunodeficiency VirusUnited States, Belgium, France, Germany, Spain, Canada, Italy, Portugal, Romania, Austria, Switzerland, Poland, Latvia, Luxembourg
-
GlaxoSmithKlineCompletedHIV Infection | Infection, Human Immunodeficiency VirusUnited States
-
ViiV HealthcareGlaxoSmithKline; ShionogiCompletedHIV Infection | Infection, Human Immunodeficiency VirusUnited States
-
Janssen-Cilag International NVCompletedHuman Immunodeficiency Virus (HIV) Infections | Acquired Immunodeficiency Syndrome (AIDS) VirusFrance, United Kingdom, Belgium, Germany, Spain, Switzerland, Denmark, Israel, Austria, Poland, Hungary, Sweden, Ireland
-
Merck Sharp & Dohme LLCRecruitingHuman Immunodeficiency Virus (HIV) InfectionUnited States, Mexico, Russian Federation, South Africa, Thailand
-
bioLytical LaboratoriesNot yet recruitingHuman Immunodeficiency Virus I Infection | Human Immunodeficiency Virus II Infection
Clinical Trials on ART first- Therapeutic use trial
-
Helsingborgs HospitalUnknown
-
University of North Carolina, Chapel HillNational Institute on Drug Abuse (NIDA); National Institute of Mental Health...Completed
-
Makerere UniversityNUFUUnknownMalnutritionNorway, Uganda
-
Colorado State UniversityThrasher Research Fund; Savica, Indonesia; Institute of Research for Development...Active, not recruitingSevere Acute MalnutritionIndonesia
-
Zhejiang Cancer HospitalUnknown
-
UNICEF - VenezuelaTerminatedWasting | Acute Malnutrition in Childhood | Child MalnutritionVenezuela
-
Infectious Diseases InstituteUniversity of Dublin, Trinity CollegeUnknown
-
Medway NHS Foundation TrustUnknownUrinary RetentionUnited Kingdom
-
University of WashingtonLa Clinique des Maladies Infectieuses, Centre Hospitalier National Universitaire...CompletedHIV and Tuberculosis Co-infection
-
International Rescue CommitteeMinistry of health, Mali; University of the Sciences, Techniques and Technologies...Active, not recruitingAcute Malnutrition in Childhood | Underweight | Acute Malnutrition in InfancyMali